Prelude Therapeutics
PRLD
75 hedge funds and large institutions have $264M invested in Prelude Therapeutics in 2026 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 13 closing their positions.
213% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 8
162% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 13
151% more capital invested
Capital invested by funds: $105M → $264M (+$159M)
50% more call options, than puts
Call options by funds: $1.15M | Put options by funds: $766K
36% more funds holding
Funds holding: 55 → 75 (+20)
13.43% more ownership
Funds ownership: 48.84% → 62.28% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$28.2M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$14.7M |
| 3 |
O
OrbiMed
New York
|
+$12.3M |
| 4 |
BlackRock
New York
|
+$6.42M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$3.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.24M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.17M |
| 3 |
Jane Street
New York
|
-$840K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$732K |
| 5 |
Goldman Sachs
New York
|
-$503K |
PRLD Hedge Fund Activity: Q2 2026 in Review
75 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q2 2026, worth a combined $264M — up 151% from $105M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PRLD positions and 13 closed out — a net gain of 21 holders — while 25 added to existing stakes and 8 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $28.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.24M sold.
- 75 institutional investors held Prelude Therapeutics (PRLD) as of Q2 2026, up from 55 in Q1 2026.
- Funds reported $264M of Prelude Therapeutics stock for Q2 2026, up 151% quarter-over-quarter.
- 34 funds opened new Prelude Therapeutics positions in Q2 2026 and 13 closed out, a net change of +21 holders.
- The largest Prelude Therapeutics buyer in Q2 2026 was RA Capital Management, an estimated $28.2M added.
- The largest Prelude Therapeutics seller in Q2 2026 was EcoR1 Capital, an estimated $3.24M sold.
Based on aggregated 13F filings for Q2 2026.